# Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients

> **NCT04982055** · PHASE4 · COMPLETED · sponsor: **Clinique Saint Pierre Ottignies** · enrollment: 60 (actual)

## Conditions studied

- Critical Illness

## Interventions

- **DRUG:** Nadroparin (intravenous Infusion)
- **DRUG:** Nadroparin (subcutaneous group)

## Key facts

- **NCT ID:** NCT04982055
- **Lead sponsor:** Clinique Saint Pierre Ottignies
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-08
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04982055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04982055, "Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04982055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*